---
layout: default
title: A systematic review of trial-matching pipelines using large language models
---

# A systematic review of trial-matching pipelines using large language models

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2509.19327" class="toolbar-btn" target="_blank">ğŸ“„ arXiv: 2509.19327v1</a>
  <a href="https://arxiv.org/pdf/2509.19327.pdf" class="toolbar-btn" target="_blank">ğŸ“¥ PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2509.19327v1" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2509.19327v1', 'A systematic review of trial-matching pipelines using large language models')" title="æ·»åŠ åˆ°æ”¶è—å¤¹">â˜† æ”¶è—</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">ğŸ”— åˆ†äº«</button>
</div>


**ä½œè€…**: Braxton A. Morrison, Madhumita Sushil, Jacob S. Young

**åˆ†ç±»**: cs.CL, cs.AI

**å‘å¸ƒæ—¥æœŸ**: 2025-09-13

**å¤‡æ³¨**: 28 pages, 3 figures

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**åˆ©ç”¨å¤§å‹è¯­è¨€æ¨¡å‹è¿›è¡Œä¸´åºŠè¯•éªŒåŒ¹é…çš„ç³»ç»Ÿæ€§ç»¼è¿°ç ”ç©¶**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **æ”¯æŸ±ä¹ï¼šå…·èº«å¤§æ¨¡å‹ (Embodied Foundation Models)**

**å…³é”®è¯**: `ä¸´åºŠè¯•éªŒåŒ¹é…` `å¤§å‹è¯­è¨€æ¨¡å‹` `è‡ªç„¶è¯­è¨€å¤„ç†` `GPT-4` `ç³»ç»Ÿæ€§ç»¼è¿°`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. äººå·¥ä¸´åºŠè¯•éªŒåŒ¹é…è€—æ—¶ä¸”æ˜“é”™ï¼Œé˜»ç¢æ–°ç–—æ³•çš„å‘ç°å’Œæ‚£è€…æ‹›å‹Ÿã€‚
2. æœ¬ç ”ç©¶ç³»ç»Ÿæ€§åœ°ç»¼è¿°äº†åŸºäºå¤§å‹è¯­è¨€æ¨¡å‹ï¼ˆLLMï¼‰çš„ä¸´åºŠè¯•éªŒåŒ¹é…æ–¹æ³•ï¼Œæ—¨åœ¨æé«˜åŒ¹é…æ•ˆç‡å’Œå‡†ç¡®æ€§ã€‚
3. ç ”ç©¶å‘ç°GPT-4åœ¨åŒ¹é…å’Œèµ„æ ¼æå–æ–¹é¢è¡¨ç°ä¼˜å¼‚ï¼Œä½†åŒæ—¶ä¹ŸæŒ‡å‡ºäº†æ•°æ®ã€æˆæœ¬å’Œä¼¦ç†ç­‰æ–¹é¢çš„æŒ‘æˆ˜ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

å°†æ‚£è€…ä¸ä¸´åºŠè¯•éªŒé€‰é¡¹è¿›è¡ŒåŒ¹é…å¯¹äºå‘ç°æ–°çš„æ²»ç–—æ–¹æ³•è‡³å…³é‡è¦ï¼Œå°¤å…¶æ˜¯åœ¨è‚¿ç˜¤å­¦é¢†åŸŸã€‚ç„¶è€Œï¼Œæ‰‹åŠ¨åŒ¹é…æ—¢è´¹åŠ›åˆå®¹æ˜“å‡ºé”™ï¼Œå¯¼è‡´æ‹›å‹Ÿå»¶è¿Ÿã€‚åŒ…å«å¤§å‹è¯­è¨€æ¨¡å‹ï¼ˆLLMï¼‰çš„æµç¨‹æä¾›äº†ä¸€ä¸ªæœ‰å¸Œæœ›çš„è§£å†³æ–¹æ¡ˆã€‚æœ¬ç ”ç©¶å¯¹2020å¹´è‡³2025å¹´é—´å‘è¡¨äºä¸‰ä¸ªå­¦æœ¯æ•°æ®åº“å’Œä¸€ä¸ªé¢„å°æœ¬æœåŠ¡å™¨çš„ç ”ç©¶è¿›è¡Œäº†ç³»ç»Ÿæ€§ç»¼è¿°ï¼Œè¯†åˆ«äº†åŸºäºLLMçš„ä¸´åºŠè¯•éªŒåŒ¹é…æ–¹æ³•ã€‚åœ¨126ç¯‡ç‹¬ç‰¹çš„æ–‡ç« ä¸­ï¼Œæœ‰31ç¯‡ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚ç»¼è¿°çš„ç ”ç©¶é›†ä¸­äºä»…æ‚£è€…-æ ‡å‡†åŒ¹é…ï¼ˆn=4ï¼‰ã€ä»…æ‚£è€…-è¯•éªŒåŒ¹é…ï¼ˆn=10ï¼‰ã€ä»…è¯•éªŒ-æ‚£è€…åŒ¹é…ï¼ˆn=2ï¼‰ã€ä»…äºŒå…ƒèµ„æ ¼åˆ†ç±»ï¼ˆn=1ï¼‰æˆ–ç»„åˆä»»åŠ¡ï¼ˆn=14ï¼‰ã€‚16é¡¹ç ”ç©¶ä½¿ç”¨äº†åˆæˆæ•°æ®ï¼›14é¡¹ç ”ç©¶ä½¿ç”¨äº†çœŸå®æ‚£è€…æ•°æ®ï¼›1é¡¹ç ”ç©¶åŒæ—¶ä½¿ç”¨äº†ä¸¤è€…ã€‚æ•°æ®é›†å’Œè¯„ä¼°æŒ‡æ ‡çš„å·®å¼‚é™åˆ¶äº†è·¨ç ”ç©¶çš„å¯æ¯”æ€§ã€‚åœ¨ç›´æ¥æ¯”è¾ƒçš„ç ”ç©¶ä¸­ï¼ŒGPT-4æ¨¡å‹åœ¨åŒ¹é…å’Œèµ„æ ¼æå–æ–¹é¢å§‹ç»ˆä¼˜äºå…¶ä»–æ¨¡å‹ï¼Œç”šè‡³æ˜¯ç»è¿‡å¾®è°ƒçš„æ¨¡å‹ï¼Œå°½ç®¡æˆæœ¬æ›´é«˜ã€‚æœ‰å¸Œæœ›çš„ç­–ç•¥åŒ…æ‹¬ä½¿ç”¨GPT-4oæ¨¡å‹ç­‰ä¸“æœ‰LLMè¿›è¡Œé›¶æ ·æœ¬æç¤ºã€é«˜çº§æ£€ç´¢æ–¹æ³•ï¼Œä»¥åŠåœ¨å°†å¤§å‹æ¨¡å‹çº³å…¥åŒ»é™¢åŸºç¡€è®¾æ–½ä¸å¯è¡Œæ—¶ï¼Œå¯¹è¾ƒå°çš„å¼€æºæ¨¡å‹è¿›è¡Œå¾®è°ƒä»¥ä¿æŠ¤æ•°æ®éšç§ã€‚å…³é”®æŒ‘æˆ˜åŒ…æ‹¬è®¿é—®è¶³å¤Ÿå¤§çš„çœŸå®ä¸–ç•Œæ•°æ®é›†ï¼Œä»¥åŠä¸éƒ¨ç½²ç›¸å…³çš„æŒ‘æˆ˜ï¼Œå¦‚é™ä½æˆæœ¬ã€å‡è½»å¹»è§‰é£é™©ã€æ•°æ®æ³„éœ²å’Œåè§ã€‚æœ¬ç»¼è¿°æ€»ç»“äº†LLMåœ¨ä¸´åºŠè¯•éªŒåŒ¹é…ä¸­çš„åº”ç”¨è¿›å±•ï¼Œå¼ºè°ƒäº†æœ‰å¸Œæœ›çš„æ–¹å‘å’Œå…³é”®é™åˆ¶ã€‚æ ‡å‡†åŒ–çš„æŒ‡æ ‡ã€æ›´çœŸå®çš„æµ‹è¯•é›†ä»¥åŠå¯¹æˆæœ¬æ•ˆç›Šå’Œå…¬å¹³æ€§çš„å…³æ³¨å¯¹äºæ›´å¹¿æ³›çš„éƒ¨ç½²è‡³å…³é‡è¦ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šä¸´åºŠè¯•éªŒåŒ¹é…æ—¨åœ¨ä¸ºæ‚£è€…æ‰¾åˆ°åˆé€‚çš„ä¸´åºŠè¯•éªŒï¼Œä¼ ç»Ÿæ–¹æ³•ä¾èµ–äººå·¥ï¼Œæ•ˆç‡ä½ä¸”å®¹æ˜“å‡ºé”™ã€‚ç°æœ‰æ–¹æ³•çš„ç—›ç‚¹åœ¨äºæ•°æ®è·å–å›°éš¾ã€åŒ¹é…è§„åˆ™å¤æ‚ã€ä»¥åŠç¼ºä¹æ ‡å‡†åŒ–çš„è¯„ä¼°ä½“ç³»ï¼Œå¯¼è‡´åŒ¹é…ç»“æœçš„å‡†ç¡®æ€§å’Œå¯ä¿¡åº¦ä¸é«˜ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šåˆ©ç”¨å¤§å‹è¯­è¨€æ¨¡å‹ï¼ˆLLMï¼‰å¼ºå¤§çš„è‡ªç„¶è¯­è¨€ç†è§£å’Œç”Ÿæˆèƒ½åŠ›ï¼Œè‡ªåŠ¨æå–æ‚£è€…ä¿¡æ¯å’Œè¯•éªŒæ ‡å‡†ï¼Œå¹¶è¿›è¡Œæ™ºèƒ½åŒ¹é…ã€‚æ ¸å¿ƒåœ¨äºå°†ä¸´åºŠè¯•éªŒåŒ¹é…é—®é¢˜è½¬åŒ–ä¸ºè‡ªç„¶è¯­è¨€å¤„ç†ä»»åŠ¡ï¼Œä¾‹å¦‚æ–‡æœ¬åˆ†ç±»ã€ä¿¡æ¯æŠ½å–å’Œè¯­ä¹‰ç›¸ä¼¼åº¦è®¡ç®—ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šæ•´ä½“æµç¨‹é€šå¸¸åŒ…æ‹¬ä»¥ä¸‹å‡ ä¸ªé˜¶æ®µï¼š1) æ•°æ®é¢„å¤„ç†ï¼šæ¸…æ´—å’Œæ ‡å‡†åŒ–æ‚£è€…ç—…å†å’Œä¸´åºŠè¯•éªŒæ–¹æ¡ˆï¼›2) ç‰¹å¾æå–ï¼šåˆ©ç”¨LLMæå–æ‚£è€…ç‰¹å¾å’Œè¯•éªŒå…¥é€‰/æ’é™¤æ ‡å‡†ï¼›3) åŒ¹é…ï¼šåŸºäºæå–çš„ç‰¹å¾ï¼Œä½¿ç”¨LLMè¿›è¡Œæ‚£è€…ä¸è¯•éªŒçš„åŒ¹é…ï¼Œè¾“å‡ºåŒ¹é…ç»“æœå’Œç½®ä¿¡åº¦ï¼›4) è¯„ä¼°ï¼šä½¿ç”¨æ ‡å‡†åŒ–çš„æŒ‡æ ‡è¯„ä¼°åŒ¹é…ç»“æœçš„å‡†ç¡®æ€§å’Œæ•ˆç‡ã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ¬ç ”ç©¶çš„å…³é”®åˆ›æ–°åœ¨äºç³»ç»Ÿæ€§åœ°ç»¼è¿°äº†LLMåœ¨ä¸´åºŠè¯•éªŒåŒ¹é…ä¸­çš„åº”ç”¨ï¼Œå¹¶æŒ‡å‡ºäº†ç°æœ‰æ–¹æ³•çš„å±€é™æ€§å’Œæœªæ¥å‘å±•æ–¹å‘ã€‚å¼ºè°ƒäº†GPT-4ç­‰å¤§å‹æ¨¡å‹åœ¨åŒ¹é…å’Œèµ„æ ¼æå–æ–¹é¢çš„ä¼˜è¶Šæ€§èƒ½ï¼Œä»¥åŠé›¶æ ·æœ¬æç¤ºå’Œå¾®è°ƒç­‰ç­–ç•¥çš„æœ‰æ•ˆæ€§ã€‚

**å…³é”®è®¾è®¡**ï¼šç ”ç©¶ä¸­æ¶‰åŠçš„å…³é”®è®¾è®¡åŒ…æ‹¬ï¼š1) å¦‚ä½•è®¾è®¡æœ‰æ•ˆçš„æç¤ºï¼ˆpromptï¼‰æ¥å¼•å¯¼LLMè¿›è¡Œä¿¡æ¯æŠ½å–å’ŒåŒ¹é…ï¼›2) å¦‚ä½•é€‰æ‹©åˆé€‚çš„LLMæ¨¡å‹ï¼Œä¾‹å¦‚GPT-4æˆ–å¼€æºæ¨¡å‹ï¼›3) å¦‚ä½•æ„å»ºæ ‡å‡†åŒ–çš„è¯„ä¼°æŒ‡æ ‡ï¼Œä¾‹å¦‚å‡†ç¡®ç‡ã€å¬å›ç‡å’ŒF1å€¼ï¼›4) å¦‚ä½•è§£å†³æ•°æ®éšç§å’Œå®‰å…¨é—®é¢˜ï¼Œä¾‹å¦‚ä½¿ç”¨åˆæˆæ•°æ®æˆ–è¿›è¡Œè”é‚¦å­¦ä¹ ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

ç ”ç©¶è¡¨æ˜ï¼ŒGPT-4æ¨¡å‹åœ¨ä¸´åºŠè¯•éªŒåŒ¹é…å’Œèµ„æ ¼æå–æ–¹é¢è¡¨ç°çªå‡ºï¼Œä¼˜äºå…¶ä»–æ¨¡å‹ï¼Œå³ä½¿æ˜¯ç»è¿‡å¾®è°ƒçš„æ¨¡å‹ã€‚é›¶æ ·æœ¬æç¤ºå’Œé«˜çº§æ£€ç´¢æ–¹æ³•ä¹Ÿè¢«è¯æ˜æ˜¯æœ‰æ•ˆçš„ç­–ç•¥ã€‚ç„¶è€Œï¼Œç ”ç©¶ä¹Ÿå¼ºè°ƒäº†æ•°æ®è·å–ã€æˆæœ¬æ§åˆ¶å’Œä¼¦ç†é—®é¢˜æ˜¯å®é™…åº”ç”¨ä¸­çš„å…³é”®æŒ‘æˆ˜ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶æˆæœå¯åº”ç”¨äºåŒ»ç–—æœºæ„ã€åˆ¶è¯å…¬å¸å’Œç ”ç©¶æœºæ„ï¼Œä»¥æé«˜ä¸´åºŠè¯•éªŒæ‹›å‹Ÿæ•ˆç‡ï¼ŒåŠ é€Ÿæ–°è¯ç ”å‘è¿›ç¨‹ã€‚é€šè¿‡è‡ªåŠ¨åŒ–åŒ¹é…ï¼Œå¯ä»¥å‡å°‘äººå·¥å¹²é¢„ï¼Œé™ä½æˆæœ¬ï¼Œå¹¶ä¸ºæ‚£è€…æä¾›æ›´å¤šä¸ªæ€§åŒ–çš„æ²»ç–—é€‰æ‹©ã€‚æœªæ¥ï¼Œè¯¥æŠ€æœ¯æœ‰æœ›ä¸ç”µå­ç—…å†ç³»ç»Ÿé›†æˆï¼Œå®ç°ä¸´åºŠè¯•éªŒçš„æ™ºèƒ½åŒ–ç®¡ç†ã€‚

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> Matching patients to clinical trial options is critical for identifying novel treatments, especially in oncology. However, manual matching is labor-intensive and error-prone, leading to recruitment delays. Pipelines incorporating large language models (LLMs) offer a promising solution. We conducted a systematic review of studies published between 2020 and 2025 from three academic databases and one preprint server, identifying LLM-based approaches to clinical trial matching. Of 126 unique articles, 31 met inclusion criteria. Reviewed studies focused on matching patient-to-criterion only (n=4), patient-to-trial only (n=10), trial-to-patient only (n=2), binary eligibility classification only (n=1) or combined tasks (n=14). Sixteen used synthetic data; fourteen used real patient data; one used both. Variability in datasets and evaluation metrics limited cross-study comparability. In studies with direct comparisons, the GPT-4 model consistently outperformed other models, even finely-tuned ones, in matching and eligibility extraction, albeit at higher cost. Promising strategies included zero-shot prompting with proprietary LLMs like the GPT-4o model, advanced retrieval methods, and fine-tuning smaller, open-source models for data privacy when incorporation of large models into hospital infrastructure is infeasible. Key challenges include accessing sufficiently large real-world data sets, and deployment-associated challenges such as reducing cost, mitigating risk of hallucinations, data leakage, and bias. This review synthesizes progress in applying LLMs to clinical trial matching, highlighting promising directions and key limitations. Standardized metrics, more realistic test sets, and attention to cost-efficiency and fairness will be critical for broader deployment.

